Q3 Earnings Forecast for CBIO Issued By HC Wainwright

Key Points

• HC Wainwright has issued a Q3 2025 EPS estimate of ($1.29) for Crescent Biopharma, with a current rating of "Buy" and a target price of $25.00.
• Other analysts have varied opinions, ranging from a "sell" rating to "strong-buy," with price targets as high as $28.00.
• Crescent Biopharma recently reported earnings of ($4.93) per share, significantly missing analysts' expectations of ($2.69).

Crescent Biopharma, Inc. (NASDAQ:CBIO - Free Report) - Analysts at HC Wainwright issued their Q3 2025 EPS estimates for Crescent Biopharma in a note issued to investors on Monday, August 11th. HC Wainwright analyst M. Kapoor anticipates that the biopharmaceutical company will post earnings per share of ($1.29) for the quarter. HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for Crescent Biopharma's current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Crescent Biopharma's Q4 2025 earnings at ($1.31) EPS, FY2025 earnings at ($8.43) EPS, Q1 2026 earnings at ($1.33) EPS, Q2 2026 earnings at ($1.36) EPS, Q3 2026 earnings at ($1.38) EPS, Q4 2026 earnings at ($1.42) EPS and FY2026 earnings at ($5.49) EPS.

Other analysts have also recently issued reports about the stock. TD Cowen upgraded shares of Crescent Biopharma to a "strong-buy" rating in a research note on Friday, June 20th. Wedbush began coverage on shares of Crescent Biopharma in a research note on Monday, July 14th. They issued an "outperform" rating and a $27.00 price objective for the company. Lifesci Capital upgraded shares of Crescent Biopharma to a "strong-buy" rating and set a $22.00 price target on the stock in a research report on Wednesday, June 18th. Wall Street Zen lowered shares of Crescent Biopharma from a "hold" rating to a "sell" rating in a research report on Saturday, August 2nd. Finally, Stifel Nicolaus initiated coverage on shares of Crescent Biopharma in a research report on Wednesday, June 25th. They issued a "buy" rating and a $28.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $25.50.

Crescent Biopharma Trading Down 1.0%

CBIO traded down $0.14 on Wednesday, reaching $13.79. 31,906 shares of the company traded hands, compared to its average volume of 92,086. The stock has a market cap of $269.59 million, a P/E ratio of -0.39 and a beta of 1.51. The business has a 50 day moving average price of $13.88. Crescent Biopharma has a 52-week low of $10.83 and a 52-week high of $63.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CBIO. BVF Inc. IL bought a new position in shares of Crescent Biopharma during the 2nd quarter worth approximately $22,400,000. Perceptive Advisors LLC bought a new position in shares of Crescent Biopharma during the 2nd quarter worth approximately $7,322,000. Commodore Capital LP bought a new position in shares of Crescent Biopharma during the 2nd quarter worth approximately $7,322,000. Frazier Life Sciences Management L.P. bought a new position in shares of Crescent Biopharma during the 2nd quarter worth approximately $7,322,000. Finally, Soleus Capital Management L.P. bought a new position in shares of Crescent Biopharma in the second quarter valued at $6,456,000. Institutional investors and hedge funds own 75.19% of the company's stock.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.